Rabeprazole na 20mg ec tab - Rabeprazole Dosage and Administration
It works by slowing or preventing the production of acid in the stomach. Rabeprazole is used to treat and maintain healing of gastroesophageal reflux disease GERD. It is also used to treat symptoms, such as heartburn and regurgitation, of non-erosive reflux disease NERD. It is also used for short-term treatment in the healing and relief of symptoms associated with duodenal and gastric ulcers. Rabeprazole is used in combination with antibiotics to treat ulcers caused by the bacterium Helicobacter pylori.
Finally, rabeprazole is used for long-term treatment of conditions associated with constant production of excess acid in the stomach, including Zollinger-Ellison syndrome. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here.
As well, some forms of this medication may not be used for all of the conditions discussed here. Your doctor may have suggested this medication for conditions other than those listed in these drug information articles.
If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor. Avoiding rabeprazole during breastfeeding confers to lowest possible risk.
Kidney or liver problems[ edit ] In people that have kidney or liver problems, these problems do not appear to affect rabeprazole's metabolism in a clinically meaningful way. This includes individuals on dialysis for kidney problems. Severe liver problems like cirrhosis of the liver do affect rabeprazole's elimination half-life, but not to a degree of dangerous accumulation. A selective pattern C—see below for a discussion of cross-reactivity patterns type I hypersensitivity reaction to rabeprazole resulting in anaphylaxis has been reported, as well as several whole group hypersentivities.
Whole group hypersentivity occurs when a person is cross-reactive to all PPIs; that is, all PPIs will induce the allergy. In pattern A, a person may be allergic to omeprazole, esomeprazole, and pantoprazole, but not to lansoprazole and rabeprazole. This is thought to be due to the structural similarities between omeprazole, esomeprazole, and pantoprazole, contrasted with lansoprazole and rabeprazole. Proton Pump Inhibitors may increase the absorption of Dextroamphetamine.
Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release XR capsules may be increased in the first hours after dosing. Proton Pump Inhibitors may decrease the bioavailability of Doxycycline.
Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring. Consider therapy modification Enzalutamide: Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.
Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring. Consider therapy modification Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.
May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may decrease the serum concentration of Gefitinib. Avoid use of proton pump inhibitors PPIs with gefitinib when possible. If required, administer gefitinib 12 hours after administration of the PPI or 12 hours before the next dose of the PPI.
Consider therapy modification Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir. Monitor therapy Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.
Proton Pump Inhibitors may decrease the serum concentration of Itraconazole. Consider therapy modification Ketoconazole Systemic: Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole Systemic. Ketoconazole Systemic may increase the serum concentration of Proton Pump Inhibitors. Consider therapy modification Ledipasvir: Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir. PPI doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions.
Consider therapy modification Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Consider avoiding concurrent administration of high-dose proton pump inhibitors PPIs with sustained-release mesalamine products. Consider therapy modification Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.
Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules Ritalin LA brand , which could result in both increased absorption early and decreased delayed absorption. The maximum reported overdose was 80 mg. There were no clinical signs or symptoms associated with any reported overdose. Patients with Zollinger-Ellison syndrome have been treated with up to mg Rabeprazole once daily.
No specific antidote for Rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.
If over-exposure occurs, call your Poison Control Center at for current information on the management of poisoning or overdosage. It is a substituted benzimidazole known chemically as 2-[[[4- 3-methoxypropoxy methylpyridinyl]-methyl]sulfinyl]-1H—benzimidazole sodium salt. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform and ethyl acetate and insoluble in ether and n-hexane. The stability of Rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions.
The structural figure is: Figure 1 Rabeprazole Sodium Delayed-Release Tablets are available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of Rabeprazole sodium. Inactive ingredients of the 20 mg tablet are diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, light magnesium oxide, low substituted hydroxypropyl cellulose, magnesium stearate, mannitol, talc, and titanium dioxide.
Iron oxide yellow is the coloring agent for the tablet coating. The ink pigment contains ammonium hydroxide, black iron oxide, propylene glycol, and shellac glaze modified in SD Because this enzyme is regarded as the acid proton pump within the parietal cell, Rabeprazole has been characterized as a gastric proton-pump inhibitor.
Rabeprazole blocks the final step of gastric acid secretion. The inhibitory effect of rabeprazole sodium on acid secretion increases slightly with repeated once-daily dosing, achieving steady state inhibition after three days.
When the drug is discontinued, secretory activity normalises over 2 to 3 days. Decreased gastric acidity due to any means, including proton pump inhibitors such as rabeprazole, increases counts of bacteria normally present in the gastrointestinal tract.
Treatment with proton pump inhibitors may possibly increase the risk of gastrointestinal infections such as Salmonella, Campylobacter and Clostridium difficile. In clinical studies patients were treated once daily with 10 or 20 mg rabeprazole sodium, for up to 43 months duration. Serum gastrin levels increased during the first 2 to 8 weeks reflecting the inhibitory effects on acid secretion and remained stable while treatment was continued.
Gastrin values returned to pre-treatment levels, usually within 1 to 2 weeks after discontinuation of therapy. Human gastric biopsy specimens from the antrum and the fundus from over patients receiving rabeprazole or comparator treatment for up to 8 weeks have not detected changes in ECL cell histology, degree of gastritis, incidence of atrophic gastritis, intestinal metaplasia or distribution of H.
In over patients followed for 36 months of continuous therapy, no significant change in findings present at baseline was observed. Systemic effects of rabeprazole sodium in the CNS, cardiovascular and respiratory systems have not been found to date. Rabeprazole sodium, given in oral doses of 20 mg for 2 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, oestrogen, testosterone, prolactin, cholecystokinin, secretin, glucagon, follicle stimulating hormone FSH , luteinising hormone LH , renin, aldosterone or somatotrophic hormone.
Rabeprazole Sodium 10 mg Gastro-resistant tablets
Always discuss possible side effects with a healthcare provider who knows your medical history, rabeprazole na 20mg ec tab. If tab are not sure what to do after missing a dose, contact your doctor or 20mg for advice. As in nonpregnant patients, lifestyle modifications followed by other medications are the initial treatments 20mg ; Huerta-Iga ; Katz ; van der Woude Proton Pump Inhibitors may decrease the serum concentration of Delavirdine, rabeprazole na 20mg ec tab. Proton Pump Inhibitors may increase the serum concentration of Tacrolimus Systemic. No rabeprazole differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Studies of this drug in pregnant animals have not shown risk to the fetus. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules Focalin XR brandwhich could result in both increased absorption early and decreased delayed absorption. In treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with Rabeprazole sodium is first initiated in such patients see section 4. Bone Fracture Several published observational studies in adults suggest that PPI therapy may be associated with an increased risk for osteoporosis -related fractures of the hip, wristor flagyl 400mg. The stability of Tab sodium is a function rabeprazole pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. Lactation Risk Summary Lactation studies have not been conducted to assess the presence of Rabeprazole in human milk, the effects of 20mg on the breastfed infant, or the effects of Rabeprazole on milk production. If concomitant therapy cannot be avoided, monitor for diminished effects of both drugs. Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity. However, whether the effect of omeprazole and esomeprazole on clopidogrel's metabolism actually leads to poor clinical outcomes is still a matter of intense debate among healthcare professionals. Co-administration of PPIs in healthy subjects and rabeprazole transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid MPApossibly due to a decrease in MMF solubility at an increased gastric pH. Whole group hypersentivity occurs when a person is cross-reactive to all PPIs; that is, all PPIs tab induce the allergy.